INS and Hyperinsulinemia: Reasons that have been postulated for this decreased mortality include that the use of pioglitazone may reduce insulin requirement and subsequently, dosage, with lower insulin, leading to a reduced rate of atherosclerotic changes induced by hyperinsulinemia [31], increase in mean low-density lipoprotein (LDL) particle size [32], and reduction in inflammatory factors [33].